IMRX - Immuneering Corporation Stock Price, Fair Value and News

$2.00+0.16 (+8.70%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

IMRX Price Action

Last 7 days

22.7%

Last 30 days

-2.0%

Last 90 days

-37.7%

Trailing 12 Months

-71.4%

IMRX RSI Chart

IMRX Valuation

Market Cap

59.2M

Price/Earnings (Trailing)

-1.02

Price/Sales (Trailing)

161

EV/EBITDA

-0.12

Price/Free Cashflow

-1.13

IMRX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

IMRX Fundamentals

IMRX Revenue

Revenue (TTM)

317.0K

IMRX Earnings

Earnings (TTM)

-58.1M

Earnings Growth (Yr)

-15.9%

Earnings Growth (Qtr)

-3.68%

IMRX Profitability

Operating Margin

100.00%

EBT Margin

-15937.29%

Return on Equity

-100.6%

Return on Assets

-84.7%

Free Cashflow Yield

-88.63%

IMRX Investor Care

Shares Dilution (1Y)

5.31%

Diluted EPS (TTM)

-1.96

IMRX Alerts

CITADEL ADVISORS LLC reported owning 0% of IMRX [2024-11-14]

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2022	1.5M	949.8K	506.1K	317.0K
2021	2.3M	2.2M	2.1M	2.1M
2020	0	0	0	2.3M

Get all data in R, Python etc through our Historical Stock Data APIs

About Immuneering Corporation

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 currently in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

CEO	Dr. Benjamin J. Zeskind M.B.A., MBA, Ph.D.
WEBSITE	https://immuneering.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	66

Immuneering Corporation Frequently Asked Questions

What is the ticker symbol for Immuneering Corporation? What does IMRX stand for in stocks?

IMRX is the stock ticker symbol of Immuneering Corporation. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Immuneering Corporation (IMRX)?

As of Fri Dec 20 2024, market cap of Immuneering Corporation is 59.25 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of IMRX stock?

You can check IMRX's fair value in chart for subscribers.

Is Immuneering Corporation a good stock to buy?

The fair value guage provides a quick view whether IMRX is over valued or under valued. Whether Immuneering Corporation is cheap or expensive depends on the assumptions which impact Immuneering Corporation's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for IMRX.

What is Immuneering Corporation's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, IMRX's PE ratio (Price to Earnings) is -1.02 and Price to Sales (PS) ratio is 161. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. IMRX PE ratio will change depending on the future growth rate expectations of investors.